Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops, and markets pharmaceuticals worldwide. With a strong focus on neurology and oncology, Eisai is dedicated to addressing unmet medical needs and increasing the benefits for patients and their families. The company's hhc philosophy emphasizes understanding the perspectives of patients to develop innovative solutions.
Serves as the global command center for strategic planning, research and development direction, corporate governance, financial management, and global administrative functions for Eisai's worldwide operations.
Modern, purpose-built facilities integrating advanced research laboratories and corporate offices. The design likely reflects Japanese efficiency and a commitment to sustainability and innovation.
Deeply rooted in its 'human health care' (hhc) philosophy, fostering a patient-centric environment. Emphasis on scientific rigor, ethical conduct, collaboration, and continuous learning. Influenced by Japanese corporate values of precision and long-term vision.
The Tokyo headquarters is pivotal for driving Eisai's global mission to make contributions to patients and society through the creation of innovative drugs in areas of high unmet medical needs, particularly neurology and oncology.
Eisai Co., Ltd. maintains a robust global presence with operations spanning Japan, the Americas, Europe, and Asia. The company supports worldwide functions including cutting-edge research and development, advanced pharmaceutical manufacturing, and comprehensive marketing and sales networks. This global footprint enables Eisai to deliver its innovative medicines and health care solutions to patients in numerous countries, addressing critical unmet medical needs on an international scale.
Koishikawa 4-6-10
Bunkyo-ku
Tokyo
Japan
Address: 200 Metro Boulevard, Nutley, NJ 07110, USA
Acts as the primary hub for Eisai's operations in the Americas, driving market access, product commercialization, and engagement with healthcare professionals and patient communities in the region.
Address: Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, AL10 9SN, UK
Strategic center for Eisai's European operations, coordinating product launches, regulatory affairs, market development, and scientific collaborations throughout the EMEA region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Eisai Co., Ltd.' leadership includes:
Eisai Co., Ltd. has been backed by several prominent investors over the years, including:
Eisai Co., Ltd. announced key leadership appointments and transitions in early 2023, aimed at strengthening its global operations and strategic focus, particularly with the appointment of a new COO.
Discover the tools Eisai Co., Ltd. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Eisai Co., Ltd. typically utilizes standardized email formats for its corporate communications. While multiple formats might exist, a common structure is often [first_initial][last] or [first].[last] @domain.com. For Eisai, the primary domain is eisai.com for global communications and eisai.co.jp for Japan.
[first].[last]@eisai.com or [first_initial][last]@eisai.com
Format
john.smith@eisai.com
Example
80%
Success rate
Eisai Co., Ltd. News Release • January 9, 2024
Eisai Co., Ltd. announced that LEQEMBI® Intravenous Infusion (lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, was approved by the National Medical Products Administration (NMPA) of China as a treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively known as early AD)....more
Eisai Co., Ltd. Investor Relations • February 7, 2024
Eisai reported its consolidated financial results for the third quarter of fiscal year 2023 (ended December 31, 2023). The company highlighted revenue growth driven by global products such as LEQEMBI and LENVIMA, and provided updates on its R&D pipeline, particularly in oncology and neurology, reaffirming its full-year guidance....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Eisai Co., Ltd., are just a search away.